Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

NCT03669965 is registered in ClinicalTrials.gov with Kartos Therapeutics, Inc. as lead sponsor.

NCT NCT03669965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Lead sponsor
Kartos Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 15, 2019
Completion date
October 31, 2022
Enrollment
20 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera